Table 5.
MRD evaluation in hemodiluted BM samples. NGS-based MRD measurements for two MM patients (pt) whose BM samples were progressively diluted with PB, to obtain 4 different cases: nonHD, MHD, MHDlow, and HD. MRD measures are quantified by the LymphoTrack® MRD Software (In vivoscribe Inc, San Diego, CA, USA). In bold: Results are an estimate of the clonal frequency of the prevalent rearrangement(s) detected at diagnosis. For each sensitivity level indicated, the statistical confidence of the result is reported.
| 1pt1 nonHD | pt1 MHD | pt1 MHDlow | pt1 HD | pt2non HD | pt2 MHD | pt2 MHDlow | pt2 HD | |
|---|---|---|---|---|---|---|---|---|
| MRD measure | 1.74x10-5 | 2.44x10-5 | 1.46x10-5 | 9.11x10-6 | 0 | 0 | 0 | 0 |
| Confidence 10-3 | 100% | 100% | 100% | 100% | 99.99% | 99.99% | 99.99% | 99.99% |
| Confidence 10-4 | 99.74% | 99.99% | 99.99% | 99.99% | 99.99% | 99.99% | 99.99% | 84.71% |
| Confidence 10-5 | 80.37% | 10.75% | 15.12% | 25.86% | 96.68% | 77.01% | 80.51% | 14.51% |
| Confidence 10-6 | 0.18% | 1.52% | 0.06% | 0.11% | 12.45% | 7.57% | 3.71% | 1.52% |
| Result | 2POS(80% at 10-5) | 3NEG(99% at 10-4) | NEG(99% at 10-4) | NEG(99% at 10-4) | NEG(97% at 10-5) | NEG(99% at 10-4) | NEG(99% at 10-4) | NEG(99% at 10-3) |
1pt: patient; 2POS (positive); 3NEG (negative).